Gee AP - Search Results

1

Shpall EJ, Gee AP, Hogan C, Cagnoni P, Gehling U, Hami L, Franklin W, Bearman SI, Ross M, Jones RB. Shpall EJ, et al. Among authors: gee ap. Hematol Oncol Clin North Am. 1996 Apr;10(2):321-43. doi: 10.1016/s0889-8588(05)70341-5. Hematol Oncol Clin North Am. 1996. PMID: 8707758 Review.

2

Stem cell isolation.

Shpall EJ, Gee A, Cagnoni PJ, Hogan C, Gehling U, Hami L, Franklin W, Bearman SI, Ross M, Jones RB. Shpall EJ, et al. Curr Opin Hematol. 1995 Nov;2(6):452-9. doi: 10.1097/00062752-199502060-00009. Curr Opin Hematol. 1995. PMID: 9372035 Review.

3

Isolation of CD34-positive hematopoietic progenitor cells.

Shpall EJ, Gehling U, Cagnoni P, Purdy M, Hami L, Gee AP. Shpall EJ, et al. Among authors: gee ap. Immunomethods. 1994 Dec;5(3):197-203. doi: 10.1006/immu.1994.1056. Immunomethods. 1994. PMID: 7540099 Review. No abstract available.

4

Immunomagnetic purging of bone marrow: a model for negative cell selection.

Pole JG, Gee A, Janssen W, Lee C, Gross S. Pole JG, et al. Am J Pediatr Hematol Oncol. 1990 Fall;12(3):257-61. doi: 10.1097/00043426-199023000-00002. Am J Pediatr Hematol Oncol. 1990. PMID: 2240471 Review.

5

Are we ready for regulation? ISHAGE Regulatory Action Group. International Society for Hematotherapy and Graft Engineering.

Collins N, Gee A, Rowley S, Shpall E. Collins N, et al. J Hematother. 1995 Feb;4(1):1-2. doi: 10.1089/scd.1.1995.4.1. J Hematother. 1995. PMID: 7757394 No abstract available.

6

Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial.

de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, Hosing C, Khouri I, Jones R, Champlin R, Karandish S, Sadeghi T, Peled T, Grynspan F, Daniely Y, Nagler A, Shpall EJ. de Lima M, et al. Bone Marrow Transplant. 2008 May;41(9):771-8. doi: 10.1038/sj.bmt.1705979. Epub 2008 Jan 21. Bone Marrow Transplant. 2008. PMID: 18209724 Free PMC article. Clinical Trial.

7

High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer.

Braunschweig I, Mirza NQ, Rondon G, Lauppe J, Mehra R, Gajewski J, Körbling M, Huh YO, Geisler D, Gee AP, Champlin R, Przepiorka D. Braunschweig I, et al. Among authors: gee ap. Cytotherapy. 2000;2(2):105-10. doi: 10.1080/146532400539107. Cytotherapy. 2000. PMID: 12042047 Clinical Trial.

8

Quantitation of tumor cell removal from bone marrow: a preclinical model.

Moss TJ, Xu ZJ, Mansour VH, Hardwick A, Kulcinski D, Ishizawa L, Law P, Gee A. Moss TJ, et al. J Hematother. 1992 Spring;1(1):65-73. doi: 10.1089/scd.1.1992.1.65. J Hematother. 1992. PMID: 1365018

9

Low antigen density tumor cells: an obstacle to effective autologous bone marrow purging?

Boyle MD, Gee AP. Boyle MD, et al. Among authors: gee ap. Cancer Invest. 1987;5(2):113-8. doi: 10.3109/07357908709018465. Cancer Invest. 1987. PMID: 3300891 Review.

10

Monoclonal antibodies and magnetic microspheres for the depletion of leukaemic cells from bone marrow harvested for autologous transplantation.

Kemshead JT, Treleaven J, Heath L, Meara AO, Gee A, Ugelstad J. Kemshead JT, et al. Bone Marrow Transplant. 1987 Aug;2(2):133-9. Bone Marrow Transplant. 1987. PMID: 3332162

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

215 results

Search Page

Filters